For disease-specific survival (DSS) outcomes, highly expressed MeCP2 was correlated with a better prognosis of DSS for cancers of BLCA, CESC, KIRC, LUAD, MESO, and UCEC, and was linked with poor prognosis of DSS for cancers of ACC, COAD, HNSC, KICH, LIHC, LUSC, SKCM, THCA, and UVW, P < 0.05 for all (Fig. S3A). Here, MECP2 is linked to bladder transitional cell carcinoma.